This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies - Novartis (NYSE:NVS) : vimarsana.com

This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies - Novartis (NYSE:NVS)

Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increased tolerance in patients aged 1-55. FDA-approved expanded use for IgE-mediated food allergies.

Related Keywords

United States , American , , American Academy Of Allergy , Roche Holdings Agrhhbyannounced , National Institutes Of Health , Roche Holdings , National Institutes , New England Journal , Immunology Annual ,